Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - A phase I study

Radiation Oncology

Volumn 1, Issue 1, 2006, Pages

  Ganswindt, Ute ^a   Budach, Wilfried ^b   Jendrossek, Verena ^a   Becker, G ^c   Bamberg, Michael ^a   Belka, Claus ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c KLINIK AM EICHERT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE;

EID: 36049029785     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-1-9     Document Type: Article

References (79)

1. Potosky AL Legler J Albertsen PC Stanford JL Gilliland FD Hamilton AS Eley JW Stephenson RA Harlan LC Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the Prostate Cancer Outcomes Study J Natl Cancer Inst 2000 92 1582-1592 10.1093/jnci/ 92.19.1582
2. Fiveash JB Hanks G Roach M Wang S Vigneault E McLaughlin PW Sandler HM 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: A multi-institutional review Int J Radiat Oncol Biol Phys 2000 47 335-342 10.1016/S0360-3016(00)00441-7 10802357
3. Valicenti R Lu J Pilepich M Asbell S Grignon D Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials J Clin Oncol 2000 18 2740-2746 10894874
4. Kupelian PA Buchsbaum JC Reddy CA Klein EA Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10) Int J Radiat Oncol Biol Phys 2001 50 621 625 10.1016/ S0360-3016(01)01466-3 11395228
5. Zelefsky MJ Fuks Z Hunt M Lee HJ Lombardi D Ling CC Reuter VE Venkatraman ES Leibel SA High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer J Urol 2001 166 876-881 10.1016/S0022-5347(05)65855-7 11490237
6. Pollack A Zagars GK Starkschall G Antolak JA Lee JJ Huang E von Eschenbach AC Kuban DA Rosen I Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 2002 53 1097-1105 10.1016/S0360-3016(02)02829-8 12128107
7. Levegrun S Jackson A Zelefsky MJ Venkatraman ES Skwarchuk MW Schlegel W Fuks Z Leibel SA Ling CC Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer Radiother Oncol 2002 63 11-26 10.1016/ S0167-8140(02)00062-2 12065099
8. Hanks GE Hanlon AL Epstein B Horwitz EM Dose response in prostate cancer with 8-12 years' follow-up Int J Radiat Oncol Biol Phys 2002 54 427-435 10.1016/S0360-3016(02)02954-1 12243818
9. Ganswindt U Paulsen F Anastasiadis AG Stenzl A Bamberg M Belka C 70 Gy or more: Which dose for which prostate cancer? J Cancer Res Clin Oncol 2005 131 407-419 10.1007/s00432-005-0681-0 15887028
10. Ganswindt U Paulsen F Corvin S Eichhorn K Glocker S Hundt I Birkner M Alber M Anastasiadis A Stenzl A Bares R Budach W Bamberg M Belka C Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition BMC Cancer 2005 5 91 1190164 16048656 10.1186/1471-2407-5-91
11. Cella L Lomax A Miralbell R Potential role of intensity modulated proton beams in prostate cancer radiotherapy Int J Radiat Oncol Biol Phys 2001 49 217-223 10.1016/S0360-3016(00)01368-7 11163518
12. Xia P Pickett B Vigneault E Verhey LJ Roach M Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy Int J Radiat Oncol Biol Phys 2001 51 244-254 10.1016/ S0360-3016(01)01643-1 11516874
13. Slater JD Rossi CJJ Yonemoto LT Bush DA Jabola BR Levy RP Grove RI Preston W Slater JM Proton therapy for prostate cancer: The initial Loma Linda University experience Int J Radiat Oncol Biol Phys 2004 59 348-352 10.1016/j.ijrobp.2003.10.011 15145147
14. Zietman AL DeSilvio ML Slater JD Rossi CJJ Miller DW Adams JA Shipley WU Yonemoto LT Mantik DW Bush DA Preston W Grove RI Slater JM Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial Jama 2005 294 1233-1239 10.1001/jama.294.10.1233 16160131
15. Mock U Bogner J Georg D Auberger T Potter R Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy Strahlenther Onkol 2005 181 448-455 10.1007/ s00066-005-1317-7 15995838
16. Zelefsky MJ Fuks Z Hunt M Yamada Y Marion C Ling CC Amols H Venkatraman ES Leibel SA High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients Int J Radiat Oncol Biol Phys 2002 53 1111-1116 10.1016/ S0360-3016(02)02857-2 12128109
17. Bolla M Gonzalez D Warde P Dubois JB Mirimanoff RO Storme G Bernier J Kuten A Sternberg C Gil T Collette L Pierart M Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 1997 337 295-300 10.1056/NEJM199707313370502 9233866
18. Bolla M Collette L Blank L Warde P Dubois JB Mirimanoff RO Storme G Bernier J Kuten A Sternberg C Mattelaer J Lopez Torecilla J Pfeffer JR Lino Cutajar C Zurlo A Pierart M Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 2002 360 103-106 10.1016/S0140-6736(02)09408-4 12126818
19. Roach M DeSilvio M Lawton C Uhl V Machtay M Seider MJ Rotman M Jones C Asbell SO Valicenti RK Han S Thomas CRJ Shipley WS Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 2003 21 1904-1911 10.1200/ JCO.2003.05.004 12743142
20. Lawton CA DeSilvio M Roach M Uhl V Krisch R Seider M Rotman M Jones C Asbell S Valicenti R Han S Thomas CR An update of the phase III trial comparing whole-pelvic to prostate only radiotherapy and neoadjuvant total androgen suppresion: Updated analysis of RTOG 94-13 Int J Radiat Oncol Biol Phys 2005 65 S 19
21. Belka C Jendrossek V Pruschy M Vink S Verheij M Budach W Apoptosis-modulating agents in combination with radiotherapy-current status and outlook Int J Radiat Oncol Biol Phys 2004 58 542-554 10.1016/ j.ijrobp.2003.09.067 14751526
22. Lammering G Anti-epidermal growth factor receptor strategies to enhance radiation action Curr Med Chem Anti-Canc Agents 2003 3 327-333 10.2174/ 1568011033482323
23. Belka C Gruber C Jendrossek V Wesselborg S Budach W The tyrosine kinase Lck is involved in regulation of mitochondrial apoptosis pathways Oncogene 2003 22 176-185 10.1038/sj.onc.1206103 12527887
24. Marini P Jendrossek V Durand E Gruber C Budach W Belka C Molecular requirements for the combined effects of TRAIL and ionising radiation Radiother Oncol 2003 68 189-198 10.1016/S0167-8140(03)00186-5 12972315
25. Marini P Schmid A Jendrossek V Faltin H Daniel PT Budach W Belka C Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis BMC Cancer 2005 5 5 547906 15651986 10.1186/ 1471-2407-5-5
26. Jendrossek V Müller I Eibel H Belka C Intracellular mediators of erucylphosphocholine-induced apoptosis Oncogene 2003 22 2621-2631 10.1038/sj.onc.1206355 12730676
27. Gupta S Crofford LJ An update on specific COX-2 inhibitors: The COXIBs Bull Rheum Dis 2001 50 1-4 12092091
28. Dannenberg AJ Altorki NK Boyle JO Dang C Howe LR Weksler BB Subbaramaiah K Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer Lancet Oncol 2001 2 544-551 10.1016/S1470-2045(01)00488-0 11905709
29. Howe LR Subbaramaiah K Brown AM Dannenberg AJ Cyclooxygenase-2: A target for the prevention and treatment of breast cancer Endocr Relat Cancer 2001 8 97-114 10.1677/erc.0.0080097 11397667
30. Thun MJ Henley SJ Patrono C Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues J Natl Cancer Inst 2002 94 252-266 11854387
31. Petersen C Baumann M Petersen S New targets for the modulation of radiation response - selective inhibition of the enzyme cyclooxygenase 2 Curr Med Chem Anti-Canc Agents 2003 3 354-359 10.2174/1568011033482314
32. Pyo H Choy H Amorino GP Kim JS Cao Q Hercules SK DuBois RN A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2 Clin Cancer Res 2001 7 2998-3005 11595687
33. Davis TW Hunter N Trifan OC Milas L Masferrer JL COX-2 inhibitors as radiosensitizing agents for cancer therapy Am J Clin Oncol 2003 26 S58-61 10.1097/00000421-200308002-00004 12902857
34. Milas L Mason KA Crane CH Liao Z Masferrer J Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme Oncology (Williston Park) 2003 17 15-24 12800601
35. Futaki N Takahashi S Yokoyama M Arai I Higuchi S Otomo S NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/ cyclooxygenase (COX-2) activity in vitro Prostaglandins 1994 47 55-59 10.1016/0090-6980(94)90074-4 8140262
36. Williams CS Mann M DuBois RN The role of cyclooxygenases in inflammation, cancer, and development Oncogene 1999 18 7908-7916 10.1038/ sj.onc.1203286 10630643
37. Siegle I Klein T Backman JT Saal JG Nusing RM Fritz P Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases Arthritis Rheum 1998 41 122-129 10.1002/ 1529-0131(199801)41:1<122::AID-ART15>3.0.CO;2-8 9433877
38. Steinbach G Lynch PM Phillips RK Wallace MH Hawk E Gordon GB Wakabayashi N Saunders B Shen Y Fujimura T Su LK Levin B The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 2000 342 1946-1952 10.1056/NEJM200006293422603 10874062
39. Hsu AL Ching TT Wang DS Song X Rangnekar VM Chen CS The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2 J Biol Chem 2000 275 11397-11403 10.1074/jbc.275.15.11397 10753955
40. Jendrossek V Handrick R Belka C Celecoxib activates a novel mitochondrial apoptosis signaling pathway Faseb J 2003 17 1547-1549 12824303
41. Grosch S Tegeder I Niederberger E Brautigam L Geisslinger G COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib Faseb J 2001 15 2742-2744 11606477
42. Jiang XH Lam SK Lin MC Jiang SH Kung HF Slosberg ED Soh JW Weinstein IB Wong BC Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protei kinase C-beta(1)-dependent pathway Oncogene 2002 21 6113-6122 10.1038/sj.onc.1205778 12203123
43. Song X Lin HP Johnson AJ Tseng PH Yang YT Kulp SK Chen CS Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells J Natl Cancer Inst 2002 94 585-591 11959891
44. Waskewich C Blumenthal RD Li H Stein R Goldenberg DM Burton J Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines Cancer Res 2002 62 2029-2033 11929821
45. Kishi K Petersen S Petersen C Hunter N Mason K Masferrer JL Tofilon PJ Milas L Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor Cancer Res 2000 60 1326-1331 10728694
46. Milas L Kishi K Hunter N Mason K Masferrer JL Tofilon PJ Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme J Natl Cancer Inst 1999 91 1501-1504 10.1093/jnci/91.17.1501 10469752
47. Sheng H Shao J Kirkland SC Isakson P Coffey RJ Morrow J Beauchamp RD DuBois RN Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2 J Clin Invest 1997 99 2254-2259 508057 9151799
48. Richter M Weiss M Weinberger I Furstenberger G Marian B Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors Carcinogenesis 2001 22 17-25 10.1093/carcin/ 22.1.17 11159736
49. Hwang D Scollard D Byrne J Levine E Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer J Natl Cancer Inst 1998 90 455-460 10.1093/jnci/90.6.455 9521170
50. Soslow RA Dannenberg AJ Rush D Woerner BM Khan KN Masferrer J Koki AT COX-2 is expressed in human pulmonary, colonic, and mammary tumors Cancer 2000 89 2637-2645 10.1002/ 1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B 11135226
51. Lin MT Lee RC Yang PC Ho FM Kuo ML Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway J Biol Chem 2001 276 48997-49002 10.1074/jbc.M107829200 11585835
52. Komhoff M Guan Y Shappell HW Davis L Jack G Shyr Y Koch MO Shappell SB Breyer MD Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas Am J Pathol 2000 157 29-35 10880372
53. Nzeako UC Guicciardi ME Yoon JH Bronk SF Gores GJ COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells Hepatology 2002 35 552-559 10.1053/jhep.2002.31774 11870367
54. Souza RF Shewmake K Beer DG Cryer B Spechler SJ Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells Cancer Res 2000 60 5767-5772 11059772
55. Pruthi RS Derksen E Gaston K Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: A review J Urol 2003 169 2352-2359 10.1097/01.ju.0000047364.56051.74 12771797
56. Liu XH Yao S Kirschenbaum A Levine AC NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells Cancer Res 1998 58 4245-4249 9766645
57. Gupta S Srivastava M Ahmad N Bostwick DG Mukhtar H Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma Prostate 2000 42 73-78 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G 10579801
58. Yoshimura R Sano H Masuda C Kawamura M Tsubouchi Y Chargui J Yoshimura N Hla T Wada S Expression of cyclooxygenase-2 in prostate carcinoma Cancer 2000 89 589-596 10.1002/ 1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C 10931458
59. Lee LM Pan CC Cheng CJ Chi CW Liu TY Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia Anticancer Res 2001 21 1291-1294 11396201
60. Kamijo T Sato T Nagatomi Y Kitamura T Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines Int J Urol 2001 8 S35-9 10.1046/j.1442-2042.2001.00332.x 11442675
61. Patel MI Subbaramaiah K Du B Chang M Yang P Newman RA Cordon-Cardo C Thaler HT Dannenberg AJ Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism Clin Cancer Res 2005 11 1999-2007 10.1158/1078-0432.CCR-04-1877 15756026
62. Dawson NA Slovin SF Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer Urology 2003 62 Suppl 1 102-118 10.1016/j.urology.2003.10.027 14747048
63. Pruthi RS Derksen JE Moore D A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy BJU Int 2004 93 275-278 10.1111/j.1464-410X.2004.04601.x 14764122
64. Steinauer KK Gibbs I Ning S French JN Armstrong J Knox SJ Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells Int J Radiat Oncol Biol Phys 2000 48 325-328 10.1016/ S0360-3016(00)00671-4 10974444
65. Handrick R Jendrossek V Goecke B Faltin H Daniel P Budach W Belka C Effects of celecoxib and irradiation treatment on prostate cancer cell lines Radiotherapy and Oncology 2004 73 372-372
66. Gaffney D Winter K Dicker A Miller B Jhingran A Ryu J Avizonis VN Fromm M Greven K A Phase I-II Study of COX-2 Inhibitor, Celebrex (Celecoxib) and Chemoradiation in Patients With Locally Advanced Cervical Cancer: Primary Endpoint Analysis of RTOG 0128 Int J Radiat Oncol Biol Phys, 2005 63 S93-S94 10.1016/j.ijrobp.2005.07.161
67. Wachter S Gerstner N Dorner D Goldner G Colotto A Wambersie A Potter R The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 2002 52 91-100 10.1016/S0360-3016(01)01821-1 11777626
68. Storey MR Pollack A Zagars G Smith L Antolak J Rosen I Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial Int J Radiat Oncol Biol Phys 2000 48 635-642 10.1016/S0360-3016(00)00700-8 11020558
69. Lawton CA Winter K Murray K Machtay M Mesic JB Hanks GE Coughlin CT Pilepich MV Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 2001 49 937-946 10.1016/S0360-3016(00)01516-9 11240234
70. Pilepich MV Winter K John MJ Mesic JB Sause W Rubin P Lawton C Machtay M Grignon D Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 2001 50 1243-1252 10.1016/S0360-3016(01)01579-6 11483335
71. Horwitz EM Winter K Hanks GE Lawton CA Russell AH Machtay M Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy Int J Radiat Oncol Biol Phys 2001 49 947-956 10.1016/S0360-3016(00)01443-7 11240235
72. Hanks GE Pajak TF Porter A Grignon D Brereton H Venkatesan V Horwitz EM Lawton C Rosenthal SA Sandler HM Shipley WU Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 2003 21 3972 3978 10.1200/JCO.2003.11.023 14581419
73. Ryu JK Winter K Michalski JM Purdy JA Markoe AM Earle JD Perez CA Roach M Sandler HM Pollack A Cox JD Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy) Int J Radiat Oncol Biol Phys 2002 54 1036-1046 10.1016/S0360-3016(02)03006-7 12419429
74. Koper PC Stroom JC van Putten WL Korevaar GA Heijmen BJ Wijnmaalen A Jansen PP Hanssens PE Griep C Krol AD Samson MJ Levendag PC Acute morbidity reduction using 3DCRT for prostate carcinoma: A randomized study Int J Radiat Oncol Biol Phys 1999 43 727-734 10.1016/ S0360-3016(98)00406-4 10098427
75. Crane CH Mason K Janjan NA Milas L Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer Am J Clin Oncol 2003 26 S81-4 10.1097/ 00000421-200308002-00009 12902862
76. Liao Z Komaki R Milas L Yuan C Kies M Chang JY Jeter M Guerrero T Blumenschien G Smith CM Fossella F Brown B Cox JD A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer Clin Cancer Res 2005 11 3342-3348 10.1158/ 1078-0432.CCR-04-1741 15867233
77. Cerchietti LC Bonomi MR Navigante AH Castro MA Cabalar ME Roth BM Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases J Neurooncol 2005 71 73-81 10.1007/s11060-004-9179-x 15719279
78. Govindan R McLeod H Mantravadi P Fineberg N Helft P Kesler K Hanna N Stoner C Ansari R Fox E Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: Preliminary results Oncology (Williston Park) 2004 18 18-21 15685829
79. Bresalier RS Sandler RS Quan H Bolognese JA Oxenius B Horgan K Lines C Riddell R Morton D Lanas A Konstam MA Baron JA Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 2005 352 1092-1102 10.1056/NEJMoa050493 15713943